¡¸ ºô¸ô¤º¬ìÄ~Äò±Ð¨| ¡¸
¦³®Ä´Á¶¡¡G¥Á°ê 94¦~08¤ë16¤é ¦Ü 94¦~08¤ë31¤é ¤î

    Case Discussion

<Presentation of a Case>

The 52-year-old man was admitted to this hospital because of fever and diarrhea for 4 weeks.

He had been otherwise well without known systemic diseases before, with exception of an episode of herpes zoster 5 years earlier before this hospitalization. He had lived in Japan with his Japanese wife and a child over the past 11 years and returned to Taiwan 2 years earlier. Four weeks earlier prior to this admission, he began to develop intermittent fevers and diarrhea without vomiting. He had no recent travel abroad. The stools were loose, which appeared to contain blood streaks. He sought medical attention at several clinics and took medicines without benefit. The symptoms continued, followed by progressive epigastric discomfort. He was seen at another hospital where physical examination disclosed tenderness at the right lower quadrant and epigastric region. There was no jaundice, visual defects, lymphadenopathies or rebound tenderness of the abdomen. Chest and heart examinations were negative. Examination of the stool specimens revealed 4+ for occult blood and numerous leukocytes. White blood cell count was 6060 x 106/L with 61.4% neutrophils and 27.1% of lymphocytes; hemoglobin was 13.2 g/dl; and platelet count was 327 x 109 /L. GOT was 66 IU/L; ƒ×-GT was 219 IU/L and alkaline phosphatase was 488 IU/L.

Abdominal sonography and abdominal computed tomographic (CT) scan showed colonic wall thickening and three hepatic abscesses with thick walls at the right lobe. Ceftriaxone and metronidazole were instituted. CT scan-guided drainage was performed to yield chocolate-like fluid, in which Gram-stain smears did not reveal bacteria or protozoa. Colonoscopy identified multiple ulcers from ascending to descending colon. The ileum was spared. Pathology of the biopsy revealed flask-shaped ulcers, in which numerous Entamoeba histolytica with ingestion of red blood cells were identified. The titer of indirect hemaglutination (IHA) assay was 1:8192. Cultures of the liver aspirate were negative for bacteria. Monotherapy with metronidazole was continued for amebic liver abscess and colitis.

After consultation with an infectious diseases specialist, the patient  agreed to an anti-HIV antibody test, which yielded positive by ELISA. Western blot test was also positive for HIV-1 after he was referred to this hospital. Baseline CD4 lymphocyte count was 223 x 106 /L, and plasma HIV-RNA load was 77,000 copies/ml by RT-PCR. He admitted to having been a homosexual and having had multiple un-protected sexual encounters in Japan and Taiwan. He also reported that he had had ora-anal sexual practice.

<®×¨Ò»P°ÝÃD¤ÀªR>
<·R´þ¯f¬r·P¬V»Pµg¯eªü¦Ì¤Ú­ìÂηP¬V>

·P¬V¤HÃþ§K¬Ì¯Ê¥F¯f¬r²Ä¤@«¬¡£Â²ºÙ·R´þ¯f¬r¡¤ªº±wªÌ¡A¸û¤@¯ë¤H®e©öµo¥Í¸z¹D­ìÂηP¬V¡A¨ä¥D­n­ì¦]¬O±wªÌªº²Ó­M§K¬Ì¡]cellular immunity¡^»PÅé²G§K¬Ì¡]humoral immunity¡^¥\¯à¡A¨ü¨ì¯}Ãa¡A³vº¥¥Ë¸Ñ¡C¦]¦¹¡A¸z¹D©è¿m«I¤J­ìÂΪº§K¬Ì¥\¯à³vº¥¤U­°¡C¸z¹D­ìÂηP¬Vªºµo¥Í¡A¥D­n¬O¦]±wªÌ¶¼¥Î¤F¦Ã¬Vªº­¹ª«©Î¶¼¤ô¦Ó¤Þ°_¸z¹Dµoª¢¯fÅÜ¡C¦Ó¨k¦P©ÊÅʱwªÌ¦b¶i¦æ¤f¥æ»P¨z¥æªº©Ê¦æ¬°¤¤¡A§ó¸û¨ä¥L±wªÌ®e©ö·P¬V¸z¹D¯f­ì¡C®Ú¾Ú°ê¥~ªº¬ã¨s¡A¦b·R´þ¯f¬r·P¬V±wªÌ¤¤¡A±`¨£¤Þ°_¸z¹Dµoª¢¯fÅܪº¸z¹D­ìÂΡA¥]¬A¡GÁô­M¤lÂΡ]Cryptosporidium parvum¡^¡BÀô­M¤lÂΡ]Cyclospora cayetanensis¡^¡Bµ¥­M¤lÂΡ]Isospora belli¡^¡Bµg¯eªü¦Ì¤Ú­ìÂΡ]Entamoeba histolytica¡^¡B±ù§ÎÃ@¤òÂΡ]Giardia lamblia¡^¡B·L­M¤lÂΡ]microsporidia¡^¡B³±¹DºwÂΡ]Trichomonas vaginalis¡^µ¥¡C¨ä¤¤³\¦h­ìÂηP¬V«á¡A³£¥i¥H³y¦¨±wªÌªø´ÁÄY­«ªº¸¡Âm¡A¾É­P±wªÌ¯Ó®z©MÀç¾i¤£¨}¡A¦p¦¹§ó­°§C¤F±wªÌ§K¬Ì¤O¡C¦³¨Ç¯f­ì¡A¨Ò¦p¡GÁô­M¤lÂΡBµ¥­M¤lÂΡBµg¯eªü¦Ì¤Ú­ìÂΡA¥i¥H«I¥Ç¤ºÅ¦¾¹©x³y¦¨¥þ¨­©Ê·P¬V¡C¦AªÌ¡A³o¨Ç­ìÂΤ]¥i¯àÂÇ·P¬VªÌ©Î°Êª«ªº±Æªnª«¡A¦Ã¬V¤F­¹ª«©M¶¼¤ô¡A¤Þ°_§ó¤jªº¬y¦æ¡C¦]¦¹¡A©M¨ä¥L«D·P¬V·R´þ¯f¬r±wªÌªº¸z¹D·P¬V¤@¯ë¡A§Ú­Ì¤]À³¯d¤ß¨ä¦¨¬°¬y¦æ©Ê¸z¹D¯e¯fªºº×·½¡C

¥Ø«e¡A¥xÆW¦a°Ï·R´þ¯f¬r·P¬V±wªÌªº²±¦æ²v¬Û¸û©ó¦è¤è©Î¨È¬w¨ä¥L°ê®a¡A¤´µM¸û§C¡CÁöµM·P¬V¤H¼Æ¤£¦h¡A¦ý¦]¬°¥xÆW¦a°Ï¦a¯U¤H¸Y¡A·¥¾A¦X¸z¹D¯f­ìªº¶Ç¼½¡C¦]¦¹¡A§Ú­Ì¥²¶·¯S§O¯d¤ß¥»¦a·R´þ¯f¬r·P¬V±wªÌ¥i¯àµo¥Íªº¸z¹D­ìÂηP¬V¡C¹L¥h¤G¤Q¦~¨Ó¡A¥xÆW¦a°Ï·R´þ¯f¬r·P¬V±wªÌ¸û±`¨£ªº¸z¹D­ìÂΪº¯f­ì¡A¦]¯Ê¥F¼sªx©M¨t²Î©Ê¬ã¨s¡A¦]¦¹¯f­ìºØÃþ¨Ã¤£²M·¡¡C®Ú¾Ú»O¤jÂå°|·R´þ¯f¨¾ªv¤¤¤ß¦b¹L¥h¤Q¦~ªºÆ[¹îµo²{¡A854¦h¦W«D¦å¤Í¯f·R´þ¯f¬r·P¬V±wªÌ¸z¹D­ìÂηP¬Vªº¯f­ì¡A¥]¬A¡G51¨Òµg¯eªü¦Ì¤Ú­ìÂγy¦¨¸zª¢©M¨xÁwºÅ¡A¤­¨ÒÁô­M¤lÂγy¦¨ªø´Á¸¡Âm¡A¤@¨ÒÁT¤p±ì½uÂΡ]Strongyloides stercoralis¡^¡B¤@¨Ò±ù§ÎÃ@¤òÂΩM¤@¨Ò³±¹DºwÂγy¦¨¸¡Âm¡C³o­ÓÆ[¹îµ²ªG¡A©M°ê¥~ªº¬ã¨sµ²ªG¤ñ¸û¡A¦³´XÂI­È±oª`·N¡G

¡]¤@¡^¡B¦è¤è·R´þ¯f±w±`¨£¤Þ°_¸¡Âmªº±H¥Í­ìÂΡA¥D­n¥]¬A¡GÁô­M¤lÂΡBÀô­M¤lÂΡBµ¥­M¤lÂλP·L­M¤lÂΡA¦b¦è¤è°ê®a³Ìªñ¹ð¦³¦]¶¼¤ô¡]¨Ò¦p¡GÁô­M¤lÂΡ^¡B¤ôªG¦Ã¬V¡]¨Ò¦p¡GÀô­M¤lÂΡ^³y¦¨³\¦h¤H¾D¨ü·P¬V¡A¨ä¤¤¤£¤Ö±wªÌµo¥Í¸ûªø´Á®É¶¡ªº¸¡Âm©MÁx¹D¯fÅÜ¡A¬Æ¦Ü¥þ¨­©Ê·P¬Vµ¥¡C¦ý¬O¡A¹L¥h³o¨Ç­ìÂΦb¥xÆW¨Ã¤£±`¨£¤Þ°_Á{§É¯f¯g¡C¹L¥h¦b¥xÆW·R´þ¯f¬r±wªÌ¨Ã¤£±`¨£³o¨Ç·P¬Vªº­ì¦]¥i¯à¬O¡G¦b¥xÆW¦a°Ï¡A±wªÌ¸û¤Ö¥Í¶¼¦Û¨Ó¤ô¡FÀËÅç¤è¦¡ªº±Ó·P«×¤£¨¬¡A¯S§O¬O·L­M¤lÂΡA¥¦»Ý­n¹q¤lÅã·LÃèÀË¡B¯S®í¬V¦â©Î§Q¥ÎPCR¤è¦¡¡A¤è¯à´£°ª¶EÂ_²v¡F±wªÌ¥i¯à¼sªx±µ¨ü§Ü·R´þ¯f¬rÃĪ«¡A§K¬Ì¤O§ïµ½¡A©ÎªÌªA¥Î³\¦h§Ü·L¥Íª«»s¾¯¡A¨Ò¦ptrimethoprim- sulfamethoxazole¡]Baktar¡^©Îmacrolides¡]azithromycin¡Bclarithromycin¡^ªº¹w¨¾ÃĪ«¡C

¡]¤G¡^¡B¥xÆW¦a°Ï·R´þ¯f¬r·P¬Vªº¨k¦P©ÊÅʪ̻·¸û°ê¥~¨k¦P©ÊÅʪ̧ó¦h·P¬Vµg¯eªü¦Ì¤Ú­ìÂΡ]E. histolytica¡^¡C¾¨ºÞ¦è¤è¾ÇªÌ¦b¨k¦P©ÊÅʪ̪º¸z¹D±Æªnª«¤¤µo²{¡A¦³¦h¹F30%¥H¤Wªº¨k¦P©ÊÅʪ̱a¦³ªü¦Ì¤Ú­ìÂΡC¦ý¬O³o¨Ç±wªÌ¸z¹D©Ò±H¥Íªºªü¦Ì¤Ú­ìÂάOÄÝ©óµL­P¯f©Ê¡]non-pathogenic amoeba¡^ªº­ìÂÎEntamoeba dispar¡A¥¦¤£·|¹³­P¯f©Êªºµg¯eªü¦Ì¤Ú­ìÂη|¤Þ°_¤j¸zª¢¡B¨xÁwºÅµ¥«I¥Ç©Êªº¯f¯g¡A¤]¤£·|§]¾½¬õ¦å²y©Î¤Þ°_±J¥D²£¥Í§ÜÅé¤ÏÀ³¡A§YÁ{§É¤H­û©Ò¼ô±xªºindirect hemagglutination (IHA)¡C¦]¦¹¡A¦b¹L¥h¤G¤Q¦~¨Ó¡A¦è¤è¾ÇªÌ¤@ª½»{¬°E. histolytica©Ò³y¦¨ªº«I¥Ç©Ê¯e¯f¡A¬O·¥¬°¨u¨£ªº¡C¦b¤@­Ó¬ü°ê¯e¯fºÞ¨î»P¹w¨¾§½¡]Centers for Disease Control and Prevention¡^¥D¾Éªº¬ã¨s¤¤¡A¦^ÅU¤F¤T¸U¦h¦ì·R´þ¯f¬r·P¬V±wªÌªº¯f¨Ò¸ê®Æµo²{¡A¶È¦³¤­¨Òªºµg¯eªü¦Ì¤Ú­ìÂηP¬V³y¦¨«I¥Ç©Ê¯e¯f¡C¦ý¬O¡A¦­¦b1987©M1989¦~¡A¸q¤j§Q¤H©M¤é¥»¤H¤À§O¦bµÛ¦WªºÂå¾Ç¤åÄmµoªí¡A¦b¤j³£·|¦a°Ïªº¨k¦P©ÊÅʪ̡A»·¸û¨k²§©ÊÅÊ©M§²¤k§ó¦h¤H¦å¤¤¥X²{°w¹ïµg¯eªü¦Ì¤Ú­ìÂΪº§ÜÅé¤ÏÀ³¡AÅã¥Ü¨k¦P©ÊÅʪ̬O·P¬Vµg¯eªü¦Ì¤Ú­ìÂΡBµo¥Í«I¥Ç©Ê·P¬Vªº°ª¦MÀI¸s¡C³o­Ó²{¶H¦b2000¦~Áú°ê­ºº¸¡]Seoul¡^·R´þ¯f¬r·P¬VªÌ©M1997©M2003¦~ªº¤é¥»´X­Ó³£·|°Ïªºµg¯eªü¦Ì¤Ú­ìÂΩҳy¦¨ªº«I¥Ç©Ê¯e¯f½Õ¬d¤¤Àò±o¤ä«ù¡C¤é¥»¦bªF¨Ê¡B¤j¨Á¡B¯«¤áµ¥³£¥«µo²{ªº55¨Òµg¯eªü¦Ì¤Ú­ìÂΩҳy¦¨ªº«I¥Ç©Ê¯e¯f¤¤¡A¶W¹L50%¬O¨k¦P©ÊÅʪ̡C³y¦¨ªF¦è¤èÆ[¹î®t²§ªº¥i¯à­ì¦]¬O¡G¬O§_ªF¤è°ê®a·R´þ¯f¬r·P¬V±wªÌ¸z¹D¥i¯à¸û¦h¤H±a¦³¨ã­P¯f¤Oªº­ìÂΡC

µg¯eªü¦Ì¤Ú­ìÂηP¬V¬OÄÝ©óªk©w¶Ç¬V¯f¡A¹L¥h¥xÆW´¿¸g¬O°ª·P¬V²±¦æ°Ï¡C¦b½Ã¥ÍÀô¹Ò§ïµ½«á¡A®×¨Ò¼Æ¤w¸g¤j´T´î¤Ö¤F¡A·sµo²{ªº­Ó®×¤j³£¶°¤¤©ó±Ò´¼±Ð¾i°|©Îºë¯«¯f°|¡C¦ý¬O¡A³Ìªñ´X¦~¨Ó¡A¥xÆW¦a°Ïªºµg¯eªü¦Ì¤Ú­ìÂηP¬V¬y¦æ¯f¾Ç¦ü¥G§ïÅܤF¡C»O¤jÂå°|·P¬V¬ìªº¬ã¨s¤H­û¦b1999¦~­º¥ý³ø§i¤F18¨Ò¨k¦P©ÊÅʪº·R´þ¯f¬r·P¬VªÌµo¥Í¤Fµg¯eªü¦Ì¤Ú¤j¸zª¢¡B¨xÁwºÅ¡C¦b³o³ø§i«á¡A³o¼Ëªº®×¨Ò¤´µM¤ÏÂЦa¥X²{¨k¦P©ÊÅʪº·R´þ¯f¬r·P¬VªÌ¨­¤W¡A¦Ó¥B¤£¤Ö¯f±wªº·R´þ¯f¬r·P¬V³Q¶EÂ_¡A¦p¦P¥»®×¨Ò¡A«Y¦]µg¯eªü¦Ì¤Ú¤j¸zª¢¡B¨xÁwºÅ¡F¥L­ÌCD4+²O¤Ú²y¤]ÅãµÛ¦a¸û¨ä¥L·R´þ¯f¬r·P¬VªÌ°ª¡C³o­Ó²{¶H¥i¯àÅã¥Ü¡Aµg¯eªü¦Ì¤Ú­ìÂΩM¤@¯ë·R´þ¯f±w±`¨£ªº¦ø¾÷©Ê·P¬V¯f­ì¤£¦P¡A¥¦¦b·R´þ¬r·P¬VªÌ§K¬Ì¥\¯àÁÙ¤£®t®É¡A§Y¥i¤Þ°_©M¤@¯ë¥¼·P¬V·R´þ¯f¬rªº¤Hµo¥Í¤j¸zª¢©Î¨xÁwºÅ¡C

ÁöµM¡A²Ó­M§K¬Ì¬O¤HÅé©è¿m³oºØ­ìÂέP¯fªº¥D­n¨¾½Ã¾÷¨î¡A¦ý¬O¡A¦b·R´þ¯f¬r·P¬VªÌ©Mªü¦Ì¤Ú­ìÂηP¬Vªº²±¦æ°Ï¡A¨Ò¦p¡G«D¬w¡BªF«n¨È¤@±a¡A«o«Ü¤Ö¦³Ãö©ó«I¥Ç©Êªºªü¦Ì¤Ú­ìÂηP¬V¡C³o­Ó®t²§²{¶H¡A¦³«Ý§ó¦hªº±H¥ÍÂξǩM¬y¦æ¯f¾Ç¬ã¨s¸Ñµª¡C

¬°¤FÁA¸Ñ¥xÆW¦a°Ï«I¥Ç©Êªü¦Ì¤Ú·P¬Vªº²±¦æ²v¡A¬O§_¦b·R´þ¯f¬r·P¬VªÌ¸û°ª¡A»O¤jÂå°|·P¬V¬ìªº¬ã¨s¤H­û°w¹ï·R´þ¯f¬r·P¬VªÌ¶i¦æ¤F¤Q¦~ªº¦^·¹©Êªº¯f¨Ò¤ÀªR¡A©M«e¤©Êªº¨â¦~ªº¦å²M¬y¦æ¯f¾Ç»P±H¥ÍÂξǪº¬ã¨s¡C¦b1994¦~¨ì2003¦~¶¡¡A¦b»O¤jÂå°|¡A¦@¦³854¦ì·R´þ¯f¬r·P¬VªÌ´NÂå¡A¨ä¤¤49¦ì(5.33%)¯f±wµo¥Í¤F51¨Ò«I¥Ç©Êªü¦Ì¤Ú·P¬V¡]¥]¬A¤j¸zª¢©Î¨xÁwºÅ¡^¡C¥L­Ìµo¯f®ÉªºCD4+§K¬Ì²y¼Æ¸û¨ä¥L¥¼µo¥Í«I¥Ç©Êªü¦Ì¤Ú·P¬VªÌ°ª¡C¦Ó¦b595¦ì±µ¨üIHA§ÜÅéÀËÅ窺·R´þ¯f¬r·P¬VªÌ¡A¦@¦³35¦ì(5.88%)§e²{°ª®Ä»ù(> = 128)¡C¦b2001¦~¨ì2003¦~¶¡¡A»O¤jÂå°|·P¬V¬ìªº¬ã¨s¤H­û¦P®É°w¹ï»O¤jÂå°|±H¥ÍÂΫǩҦ¬¨ìÀËÅçIHA¦å²MÀËÅé¡A¶i¦æ·R´þ¯f¬rªº§ÜÅé´úÅç¡A¥L­Ìµo²{405¦ì¥¼·P¬V·R´þ¯f¬rªº¤H¡A7¦ì(1.73%)§e°ª®Ä»ùªºªü¦Ì¤Ú§ÜÅé¤ÏÀ³¡F¦Ó¦b110¦ìªº·R´þ¯f¬r·P¬VªÌ¤¤¡A14¦ì(12.73%)§e°ª®Ä»ù¤ÏÀ³¡F¦AªÌ¡A¬ã¨s¤H­û¦bªù¶E¦¬¶°·R´þ¯f¬r·P¬VªÌ©M«D·P¬VªÌªºÁT«K¡A¶i¦æªü¦Ì¤Ú­ìÂΪº§Ü­ìÀËÅç¡A¥L­Ìµo²{¡A¦b303¦ì·R´þ¯f¬r·P¬VªÌ¤¤¡A43¦ì(12.68%)ªºÁT«K¤¤¡A¦³ªü¦Ì¤Ú­ì§Ü­ìªº¶§©Ê¤ÏÀ³¡C¬Û¤Ïªº¡A¦b86¦ì«D·R´þ¯f¬r·P¬VªÌ¤¤¡A¨Ã¨S¦³¥ô¦ó¤@¦ì§e¶§©Ê¤ÏÀ³¡C¦Ó¦b³o43­Ó¦¨¶§©ÊªºÀËÅ餤¡A¸g¥ÑPCR¡A¥L­Ì¤]µo²{7­ÓÀËÅé(18.42%)¡A±a¦³­P¯f©Êªü¦Ì¤Ú­ìÂΡC¦]¦¹¡A¥L­Ìªº¬ã¨sµo²{¡A«I¥Ç©Êªºªü¦Ì¤Ú­ìÂηP¬V¡A½T¹ê¦nµo©ó·R´þ¯f¬r·P¬VªÌ¡A¯S§O¬O¨k¦P©ÊÅʪ̡C¦P¼Ë¦a¡A¦¨¥\¤j¾Çªþ³]Âå°|·P¬V¬ìªº¬ã¨s¤H­û¦b2004¦~°w¹ï«n³¡¤T·Å·x¤¤148¦ì¥¼·P¬V·R´þ¯f¬rªº¨k¦P©ÊÅʪ̶i¦æIHAÀËÅç¡A¥L­Ì¤]µo²{4.8%ªº¨ü¸ÕªÌ§e²{°ª®Ä»ùªº¶§©Ê¤ÏÀ³¡C

¥Ñ¦¹µo²{¡A§Ú­Ì¥iª¾¨k¦P©ÊÅʪ̡A¤£½×¬O§_·P¬V·R´þ¯f¬r¡A¬O¨Öµo«I¥Ç©Êªü¦Ì¤Ú¯e¯f°ª¦MÀI¸s¡A¨ä¤¤­ì¦]¥i¯à¬O¦³¨Ç¨k¦P©ÊÅÊ·P¬V¤F­P¯f©Êªºµg¯eªü¦Ì¤Ú­ìÂΡAÂǥѤf¹ï¨zªùªº©Ê¦æ¬°¤è¦¡¡A¶Ç¼½ªü¦Ì¤Ú­ìÂΡC¦]¦¹¡C¥Á²³¡A¯S§O¬O¨k¦P©ÊÅʪ̡AÀ³³Q§iª¾·P¬Vªü¦Ì¤Ú­ìÂΪº³~®|©M­·ÀI¡A¨Ã¥B±Ð¨|°ª¦MÀI¸sÀ³±Ä¨ú¦w¥þªº©Ê¦æ¬°¡A¥H­°§C·P¬Vªü¦Ì¤Ú­ìÂΪº­·ÀI¡C¦P®É¡A¥Ñ¥»¨Òªº¤ÀªRªºµ²½×¬O¡A°w¹ï¦b¥xÆW¦a°Ïµo²{«I¥Ç©Êµg¯eªü¦Ì¤Ú·P¬V®É¡A¦pªG­Ó®×¨Ã¤£¬O¦b¦w¾i¤¤¤ß¡B±Ò´¼±Ð¾i°|¡B©Îºë¯«¯f°|ªº°|¥Í®É¡A§Ú­Ì¥²¶·¯d¤ß¥L¬O§_¥i¯à¬O¨k¦P©ÊÅʪ̡A¬O§_·P¬V·R´þ¯f¬r¡C

¥t¥~¡A¥»®×¨Ò­È±oª`·Nªº¬O¡G¯f±w¦b¤­¦~«e¡A·N§Y¥L47·³®É¡A´¿µo¥Í±aª¬©´¯l¡F³o·N¨ýµÛ¥L¥i¯àµo¥Í¤F§K¬Ì¨t²Î§C¤U¡C¦b¥¼±µ¨ü§K¬Ì§í¨î¾¯¡B¤Æ¾ÇÃĪ«ªvÀø©ÎªÌµo¥Í´c©Ê¸~½F©Î±µ¨ü¾¹©x²¾´Ó¡A47·³¡B¥­¤é°·±dªº¨k©Êµo¥Í±aª¬©´¯l¡A¥²¶·¦Ò¼{·R´þ¯f¬r·P¬Vªº¥i¯à©Ê¡C±wªÌµo¥ÍÄY­«ªºªü¦Ì¤Ú¤j¸zª¢»P¨xÁwºÅªº­ì¦]¡A³Ì¦³¥i¯à¬O»P¨ä¥L±a¦³­P¯f©Êµg¯eªü¦Ì¤Ú­ìÂΪº¨k¦P©ÊÅʪ̵o¥Í¤f¡B¨zªº©Ê¦æ¬°±µÄ²®É·P¬V¦Ó«áµo¯f¡C§Y«K·P¬V­P¯f©Êµg¯eªü¦Ì¤Ú­ìÂΡA±a­ìªÌ¤j¦h¼Æ¨S¦³¯f¯g¡A¦ý¬O¡A¦b¤@¦~¤§¤¤¡A¬ù¦³6-10%·|µo¥Í¯f¯g¡C¦]¦¹¡A±a¦³­P¯f©Êµg¯eªü¦Ì¤Ú­ìÂΪº·P¬VªÌ¡A¥²¶·±µ¨üÃĪ«ªvÀø¡FªvÀø©Ò¥ÎªºÃĪ«¡A°ê¤º¯e¯fºÞ¨î§½³Æ¦³ªºÃĪ«¬Oiodoquinol¡AªA¥Î21¤Ñ¡C¹ï©óµo¥Í¯f¯gªº±wªÌ¡A°£¤F¥²¶·³Æ³q³ø¦Ü¯e¯fºÞ¨î§½¥~¡A¸gÅç³Ì¦hªºÃĪ«¬Ometronidazole¡C¦b±µ¨ü7-10¤ÑªºÀøµ{«á¡A±wªÌ¤]À³¦A±µ¨ü21¤Ñªºiodoquinol¡A¥H´î¤Ö´_µo¡C

<µg¯eªü¦Ì¤Ú­ìÂηP¬V¬y¦æ¯f¾Ç>

¾¨ºÞ½Ã¥ÍÀô¹Ò§ïµ½¡Aµg¯eªü¦Ì¤Ú­ìÂΤ´µM¬O¥xÆW¦a°Ï­«­nªº±H¥ÍÂηP¬V¡C¦b¥þ²y¡Aµg¯eªü¦Ì¤Ú­ìÂηP¬V¨C¦~¤´µM³y¦¨100,000¦º¤`®×¨Ò¡Cµg¯eªü¦Ì¤Ú­ìÂΥͬ¡¥v«D±`²³æ¡A¤HÃþ«Y¦]¦Y¤U¦Ã¬V¤Fªü¦Ì¤ÚÅnÅé¡]cyst¡^ªº¶¼¤ô©Î­¹ª«·P¬V¡Aªü¦Ì¤ÚÅnÅé¦b¤p¸z²æÂ÷ÅnÅé¡A§Î¦¨Àç¾iÅé¡]trophozoite¡^¡AÀç¾iÅé¥i¯à«ùÄò±H¥Í¦b¤j¸z¤¤¡B«I¥Ç¤j¸z©Î¶i¤J¦å²G´`Àô«I¥Ç¨ä¥Lªº²Õ´¾¹©x¡F©ÎªÌ¡A¦A«×§Î¦¨ÅnÅé¡AÀHÁT«K±Æ¥X¡C¦]¦¹¤HÃþ·P¬Vµg¯eªü¦Ì¤Ú­ìÂΫá¡A¤j¦hÄÝ©óµL¯gª¬±a­ìªÌ¡A·íµM¤]¥i¯àµo¥Í¤j¸zª¢¡B²Õ´¾¹©xÁwºÅ¡A¯S§O¬O¨xÁwºÅ¡C

ªü¦Ì¤Ú­ìÂηP¬Vªº°ª¦MÀI¸s¡A¥]¬A¡G±Ò´¼±Ð¾i°|©Îºë¯«¯f°|°|¥Í¡B³Ìªñ¨ì¹L¬Ì°Ï®È¹Cªð°êªº®È«È¡B¨Ó¦Û¬Ì°Ïªº²¾¥Á¡B¨k¦P©ÊÅʪ̵¥¡C¤@¯ë¤H¹ïµg¯eªü¦Ì¤Ú­ìÂηP¬Vªº¬y¦æ¯f¾Çªº»{ª¾¡A¦b1990¦~¥N¤¤´Á¡A¹ïµg¯eªü¦Ì¤Ú­ìÂΪº¤ÀÃþ¬ã¨s§ó²M·¡«á¡A¦³¤F­«¤jªº§ïÅÜ¡Cµg¯eªü¦Ì¤Ú­ìÂΤÀ¬°¨âºØ¡G­P¯f©Ê¡A¥ç§YE. histolytica¡F»P«D­P¯f©Ê¥ç§YE. dispar¡C¹L¥h¹ï©óµg¯eªü¦Ì¤Ú­ìÂΪº¬ã¨s¡A¤j³£¥õ¿à¥ú¾ÇÅã·LÃè¡F¦ý¬O¡A¥ú¾ÇÅã·LÃè¯fµLªk¤À¿ëE. histolytica©ME. dispar¡C¦]¦¹¡A¹L¥hªº¬y¦æ¯f¾Ç¬ã¨s±À¦ô¥þ¥@¬É¬ù¦³10% E. histolytica±a­ì¡A³o­Ó¼Æ­È«Ü¥i¯à¬O°ª¦ô¤F¡C¦pªG¨Ì¿à¦å²M¾Çªº½Õ¬d¡A¥i¯à¸û¯à¤Ï¬M¥XE. histolyticaªº·P¬V²v¡A¦]¬°¥u¦³·P¬VE. histolytica¤~·|²£¥Í¦å²M§ÜÅé¤ÏÀ³¡C·P¬Vµg¯eªü¦Ì¤Ú­ìÂΡA90%¤£·|²£¥Í¯f¯g¡A¦ý¬O«e¤©Êªº¬ã¨sµo²{¡A¾¨ºÞ­è·P¬V®ÉµL¯gª¬¡A¦b¥¼¨Óªº6-12­Ó¤ë¤¤¡A¬ù9%ªº·P¬VªÌ·|µo¥Í«I¥Ç©Ê¯e¯f¡C¦Ó®Ú¾Ú¶V«nªº¬ã¨sµo²{¡A50%¥H¤W±a­ìªº®É¶¡¡A·|¶W¹L¤Q­Ó¤ë¤§¤[¡C¦]¬°«I¥Ç©Êªºµg¯eªü¦Ì¤Ú·P¬V©Ò³y¦¨ÄY­«ªº¨xÁwºÅ©Îµg¯e¡A¦º¤`²v¶W¹L10%¡A¦Ó¥B±a­ìªÌ·|¦A¶Ç¬V¥L¤H¡A¦]¦¹¡A¥ô¦ó·P¬Vµg¯eªü¦Ì¤Ú­ìÂΪ̳£À³±µ¨ü¾A·íªºªvÀø¡C

<Á{§É¯f¼x>

µg¯eªü¦Ì¤Ú·P¬V©Ò³y¦¨ªº¤j¸zª¢¯gª¬¡A¥]¬A¸¡Âm¡]³q±`¬O¦å«K¡^¡B¸¡µh©Mµo¿N¡F³o¨Ç¯gª¬¥i¯à«Ü»´·L¡A¤]¥i¯à«ÜÄY­«¡C¦]¬°¨xÁwºÅµo¥Íªº³¡¦ì¡A¥H¥k¨x¸­¬°¦h¡A¨xÁwºÅªº¯f¯g¥D­n¥Hµo¿N©M¥k¤W¸¡µh¬°¥D¡C¦pªG¨xÁwºÅ¯}µõ¡AÁw¶i¤J¯Ý¦Ø½¤¡B¤ß¥]½¤©Î¸¡½¤¡A¯f¯g¤]·|ÀH¤§§ïÅÜ¡Cµg¯eªü¦Ì¤Ú¤]·|ÀHµÛ¦å²G¨ìªÍŦ©Î¸£³¡³y¦¨ÁwºÅ¡C

<¹êÅç«Ç¶EÂ_>

¦pªG¬°¤F¶i¦æ¬y¦æ¯f¾Ç¬ã¨s©ÎÀËÅç³Ìªñ¨ì¹L¬Ì°Ï®È¹C¬O§_·P¬Vµg¯eªü¦Ì¤Ú­ìÂΡA©ÎªÌ¦b¥ú¾ÇÅã·LÃè¤U¬Ý¨ìªü¦Ì¤Ú­ìÂΡAµLªk¤À¿ë¨s³º¬OE. histolytica©Î¬OE. dispar³Ì¦nªº¤èªk¬OÀ³¥Îªü¦Ì¤Ú§Ü­ìÀË´ú¡C¥Ø«e¬ü°êFDA³q¹Lªºªü¦Ì¤Ú§Ü­ìÀË´ú¦³¨âºØ¤èªk¡Gthe TechLab E. histolytica II©MAlexon E. histolytica kits¡C¦ý¬O¡A³o¨âºØÀË´ú¤èªk¡A³£¥²¶·¨Ï¥Î·sÂA¦¬¶°ªºÁT«K¡F¦AªÌ¡Athe TechLab E. histolytica II¥i¥H¤À¿ë¥X­P¯f©ÊªºE. histolytica¡A¦ÓAlexon E. histolytica kits¥u¯à¤À¥XE. histolytica/E. dispar complex¡C¨Ï¥Î¤À¤l¥Íª«¾ÇªºPCRÀËÅçÁT«K¡A¤]¬O¤@­Ó«Ü¦nªº¤À¿ë¤èªk¡A¦ý¬O¡A¸ûthe TechLab E. histolytica II§xÃø¡C¦Ü©ó¦å²M§ÜÅ骺ÀËÅç¡A¤£¾A¥Î©ó¶EÂ_¨Ó¦Ûªü¦Ì¤Ú·P¬V¬Ì°Ïªº¦í¥Á¬O§_µo¥Í·P¬V¡A¦]¬°¸z¹D·P¬V¹L­P¯f©Êªºµg¯eªü¦Ì¤Ú­ìÂÎ¥H«á¡A50-80%·|¥X²{¶§©Ê§ÜÅé¤ÏÀ³¡C

¹ï©óªü¦Ì¤Ú¸zª¢ªº¶EÂ_¡A³Ì¦nªº¤è¦¡¬O¤j¸zÃèÀˤÁ¤ù¡A¦bÅã·LÃè¤U¬Ý¨ì¼ìºÅµoª¢¡Bªü¦Ì¤Ú­ìÂΧ]¾½¬õ¦å²yªºÅܤơC¨xÁwºÅªº¶EÂ_¡A±o¥õ¿à¸¡³¡¶W­µªi©Î¹q¸£Â_¼h¡AÂǧU¬ï¨ë¨ú±oÁwºÅ¶i¦æ²Ó­M¾Ç¡B±H¥ÍÂξÇÀËÅç¡BPCRÀËÅç©Î±H¥ÍÂξǰö¾i¡C¯f±wªº¨x¥\¯àÀˬdµ²ªG¥i¯à²§±`¡A¤]¥i¯à¥¿±`¡C¨xÁwºÅ±wªÌ¦å²M§ÜÅ骺¶§©Ê¤ÏÀ³ªº¤ñ¨Ò¥i¥H°ª¹F90%¥H¤W¡C¥Ø«e¤´¦bµû¦ô¤¤ªºÀËÅç¤èªk¡AÁÙ¦³¦å²M§Ü­ì¤ÏÀ³¡F¦n³B¬O±Ó·P«×°ª¦Ó¥B¥i¥H¥Î©ó°lÂܪvÀøÀø®Ä¡C

<µg¯eªü¦Ì¤Ú­ìÂηP¬VªºªvÀø>

¥Ø«e¹ï©óµg¯eªü¦Ì¤Ú­ìÂεL¯gª¬¸z¹D·P¬V±a­ìªºªvÀø¨ã¦³Àø®ÄªºÃĪ«¦³¤TÃþ¡Gdichloracetanilide derivatives, oral aminoglycosides, ©M 5-hydroxyquinolines¡C³o¨ÇÃĪ«¥]¬A¡Gdiloxanide furoate (Furamide), paromomycin (Humatin), ©Miodoquinol (Yodoxin¡Fdiiodohydroxyquin)¡C³o¨ÇÃĪ«ªº¤fªA§l¦¬«Ü®t¡A¦]¦¹¦b¤j¸zªºÃĪ«¿@«×°ª¡Cdiloxanide furoate ©Mparomomycin¬O¨Ï¥Î¸gÅç¸û¦h¡B±M®a¸û¬°±ÀÂ˪º­º¿ïÃĪ«¡CDiloxanide furoate¤w¸g±q1950¦~¥N¨Ï¥Î¨´¤µ¡A¥¦¬Ochloramphenicolªºªñ¿Ë¡A®Ú¾Ú¬ü°ê¯e¯fºÞ¨î§½¦b1977¨ì1990¶¡ªº¸gÅç¡A¹ï©ó·P¬VE. histolytica/E. dispar±a­ìªº±wªÌ¡A¸z¹D²M°£²v¬ù¬°86%¡F¸ÓÃĪ«ªº°Æ§@¥Î§C¡A¤j¬ù14%ªº¨Ï¥ÎªÌ·|¥X²{¸z­G¤£¾Aªº¯gª¬¡CParomomycin¹ï©ó·P¬VE. histolytica/E. dispar±a­ìªº±wªÌ°£¤F¸z¹D²M°£²v°ª¥H¥~¡A¹ï©ó»´¯gªºªü¦Ì¤Ú¸zª¢¤]¦³Àø®Ä¡FÀøµ{¬ù¬°¤C¤Ñ¡C¸ÓÃĪ«ªº°Æ§@¥Î¥D­n¤]¬O¸z­G¤£¾A¡F¦³¨Ç¤H¥i¯à¥X²{ÀY·w¡BÀYµh¡CIodoquinol¤]¬O¤@­Ó«K©y¦³®ÄªºÃĪ«¡A¦L«×ªº¬ã¨sÅã¥Ü¡A¹ï©ó«Dµg¯eªºªü¦Ì¤Ú¸zª¢¡A¸z¹D²M°£²v¬ù85%¡C±`¨£ªº°Æ§@¥Î¡A¥]¬A¡G«K¯µ©M¥Òª¬¸¢¸~¤j¡A¦]¬°¦¹ÃĪ«¤º§t64%¸K¡C

¹ï©óªü¦Ì¤Ú¤j¸zª¢ªºªvÀø³Ì¦³®ÄªG¡B¸gÅç³Ì¦hªºÃĪ«¬Onitroimidazoles¡A¯S§O¬Ometronidazole (Flagyl) ©M tinidazole (Fazigyn)¡F¨ä¥LÁÙ¦³secnidazole©M ornidazole¡CMetronidazole³Ì±`¨£ªº°Æ§@¥Î¥]¬Aäú¤ß¡B¹Ã¦R¡Bª÷Äݨý¹D¡C¸û¤Ö¨£ªº°Æ§@¥Î¬O¡A¦pªG¦P®É³Ü°s¡A¥i¯à³y¦¨disulfuram-like¤ÏÀ³¡B¹Ã¦R¡B©PÃ䯫¸gª¢¡C³o¨Çnitroimidazolesªº¤fªA§l¦¬«Ü¦n¡A¦]¦¹¹ï©ó¸z¹Dªºªü¦Ì¤ÚÀç¾iÅé®ÄªG¸û®t¡A¦]¦¹®e©ö´_µo¡C®Ú¾Ú¬ã¨s¡A¦b±µ¨ünitroimidazolesªvÀø«á¦³40-60%ªº¯f±w¸z¹D¨ÌµM¦³ªü¦Ì¤Ú­ìÂΡC¹ï©ó·¥¬°ÄY­«ªº«I¥Ç©Êµg¯eªü¦Ì¤Ú·P¬V¡A¦³¨Ç±M®a«Øij¥[¤Jemetine¡C¤£¹L¡Aemetine¨ã¦³¤ßŦ¬r©Ê¡A¦Ó¥B¥²¶·±Ä¥Î¦Ù¦×©ÎªÌ¥Ö¤Uª`®g¡C¹ï©óªü¦Ì¤Ú¤j¸zª¢¨Öµo¸z¬ï¤Õ©M¸¡½¤ª¢®É¡A¯f±wÁٻݱµ¨ü¶}¤MªvÀø¡C

µg¯eªü¦Ì¤ÚÁwºÅªºªvÀø¡A¥i¥H¨Ï¥Î°ª¾¯¶qªºmetronidazole¡]750 mg tid¡^ªvÀø10¤Ñ©Î tinidazoleªvÀø5¤Ñ¡C§¹ªv«á¡A¯f±wÁٻݱµ¨üdiloxanide furoate©Îparomomycin ¥H²M°£¸z¹D«ùÄò±a­ì¡C

Ãh¥¥°ü¤kµo¥Íµg¯eªü¦Ì¤Ú­ìÂηP¬V®É¡A¸û®e©öµo¥Í«I¥Ç©Êªº¯e¯f¡CParomomycin¬OªvÀø¸z¹D±a­ì¥i¥H¿ï¥ÎªºÃĪ«¡C¦Ü©óµo¥Í«I¥Ç©Ê·P¬V®É¡AÁ{§É¬ã¨sÅã¥Ü¡Ametronidazole¨Ã¨S¦³¤ñ¸û¹ï·Ó²Õ¡B¥¼µo¥Í«I¥Ç©Êµg¯eªü¦Ì¤Ú·P¬Vªº°ü¤k³y¦¨§ó°ªªº·î­L­·ÀI¡C

<°Ñ¦Ò¤åÄm>

  1.  Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr.. Amebiasis. N Engl J Med 2003;348:1565-73.
  2. Stanley SL Jr.. Amoebiasis. Lancet 2003;361:1025-34.
  3. Blessmann J, Ali IK, Ton Nu PA, et al. Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. J Clin Microbiol 2003;41:4745-50.
  4. Phillips SC, Mildvan D, William DC, Gelb AM, White AC. Sexual transmission of enteric protozoa and helminths in a venereal-disease-clinic population. N Engl J Med 1981;305:603-606.
  5. Quinn TC, Stamm WE, Goodell SE, et al. The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med 1983;309:576-582.
  6. Markell EK, Hanens RF, Kuritsubo RA, Wingerd J. Intestinal protozoa in homosexual men of the San Francisco Bay area: prevalence and correlates of infection. Am J Trop Med Hyg 1984;33:239-245.
  7. Allason-Jones E, Mindel A, Sargenunt P, Williams P. Entamoeba histolytica as a commensal intestinal parasite in homosexual men. N Engl J Med 1986;315:353-356.
  8. Sorvillo FJ, Strassburg MA, Seidel J, et al. Amebic infections in asymptomatic homosexual men: lack of evidence of invasive disease. Am J Public Health 1986;76:1137-1139.
  9. Lowther SA, Dworkin MS, Hanson DL, and the Adult and Adolescent Spectrum of Human Immunodeficiency Virus Disease Project. Entamoeba histolytica/Entamoeba dispar in human immunodeficiency virus-infected patients in the United States. Clin Infect Dis 2000;30:955-959.
  10. Aceti A, Pennica A, Ippolito G, et al. Antiamebic antibodies in homosexual men. N Engl J Med 1987;316:692.
  11. Takeuchi T, Okuzawa E, Nozaki T, et al. High seropositivity of Japanese homosexual men for amebic infection. J Infect Dis 1989;159:808.
  12. Ohnishi K, Murata M. Present characteristics of symptomatic amebiasis due to Entamoeba histolytica in the east-southeast area of Tokyo. Epidemiol Infect 1997;119:363-7.
  13. Ohnishi K, Kato Y, Imamura A, Fukayama M, Tsunoda T, Sakaue Y, et al. Present characteristics of symptomatic Entamoeba histolytica infection in the big cities of Japan. Epidemiol Infect 2003;132:57-60.
  14. Oh M, Lee K, Kim E, et al. Amoebic liver abscess in HIV-infected patients. AIDS 2000;14:1872-1873.
  15. Hung CC, Chen PJ, Hsieh SM, et al. Invasive amebiasis: an emerging parasitic disease in patients with HIV infection in an endemic area of amebic infection. AIDS 1999;13:2421-2428.
  16. Liu CJ, Hung CC, Chen MY, Lai YP, Chen PJ, Huang SH, Chen DS: Amebic liver abscess and human immunodeficiency virus infection: a report of three cases. J Clin Gastroenterol 2001;33:64-8.
  17. Hung CC, Deng HI, Hsiao WH, Hsieh SM, Hsiao CF, Chen MY, Chang SC, Su KE: Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan. Arch Intern Med 2005;165:409-15.
  18. Lee HC, Ko NY, Chang MP, Lee WC, Ko WC. Prevalence of HIV infection and other sexually transmitted diseases in gay saunas in Taiwan. 15th European Congress of Clinical Microbiology and Infectious Diseases. Abstract No. P690. Copenhagen, Denmark 2-5 April 2005.

Ä~Äò±Ð¨|¦ÒÃD
1.
(D)
¤U¦C­þ¨Ç¯f­ì¡A¨ã¦³¤Þ°_§K¬Ì¤£¥þ¯f±wÄY­«ªº¸¡Âm©M¸z¹D¥~·P¬Vªº¼ç¦b­·ÀI¡H
AStrongyloides stercoralis
BCryptosporidium parvum
C Nontyphoid Salmonella
D¥H¤W¬Ò¬O
2.
(D)
½Ð°Ý¥H¤U­þ¤@±Ú¸s¬Oµo¥Íªü¦Ì¤Ú·P¬Vªº°ª¦MÀI¸s¡H
Aºë¯«¯f¡B±Ò´¼±Ð¾i°|°|°|¥Í
B¨k¦P©ÊÅÊ
C¨j±qªü¦Ì¤Ú·P¬V¬Ì°Ï®È¹C¦^¨Ó
D¥H¤W¬Ò¬O
3.
(B)
¤U¦C¦óªÌµLªk¥Î¥H¤À§O·P¬Vªü¦Ì¤Ú­ìÂάOÄÝ­P¯f©Ê¡H
A¦å¤¤¥X²{ªü¦Ì¤Ú§ÜÅé
BÁT«KÀËÅ餤µo²{ªü¦Ì¤Ú­ìÂÎÅnÅé©MÀç¾iÅé
C¥X²{§]¾½¬õ¦å²yªºÀç¾iÅé
D¤j¸zÃèÀË¥X²{¿NªMª¬¼ìºÅ
4.
(C)
Ãö©óµg¯eªü¦Ì¤Ú­ìÂηP¬Vªº±Ô­z¡A¦óªÌ¬°¬O¡H
A¤j¦h¼Æ·P¬VªÌ³£·|µo¥Í¤j¸zª¢
B±a­ìªÌ¤£»ÝªvÀø
C·P¬V³~®|¬OÁT¤f¶Ç¬V
D¤£·|µo¥Í¤H¹ï¤Hª½±µ¶Ç¼½
5.
(D)
¤U¦C­þ¨Ç±J¥D·P¬Vµg¯eªü¦Ì¤Ú®É¡A®e©öµo¥Í«I¥Ç©Ê¯e¯f¡H
A¥¥°ü
B·s¥Í¨à
CªA¥Î§K¬Ì§í¨î¾¯
D¥H¤W¬Ò¬O
6.
(C)
Ãö©ó²Óµß©Ê¨xÁwºÅ»Pªü¦Ì¤Ú¨xÁwºÅªºÁ{§Éªí²{ªº®t²§¡A¦óªÌ¬°«D¡H
A¥xÆW¦a°Ï²Óµß©Ê¨xÁwºÅ¯f¦]¡A¤j¦h¬°Klebsiella pneumoniae
B¨âªÌ³£¥H¥k¨x¸­³Ì±`¨£
Cªü¦Ì¤Ú¨xÁwºÅ»P²Óµß©Ê¨xÁwºÅªºªvÀø¡A¬Ò¬O§Ü¥Í¯À¥[¤W¨x¬ï¨ë¤Þ¬y
Dªü¦Ì¤Ú¨xÁwºÅ¯f±w¬ù¤E¦¨¥H¤W¦å¤¤·|¥X²{ªü¦Ì¤Ú§ÜÅé
7.
(D)
Ãö©óµg¯eªü¦Ì¤Ú¤j¸zª¢ªº±Ô­z¡A¦óªÌ¬°¬O¡H
AªvÀøÃĪ«­º¿ï¬Ometronidazole
B¯f±w¤]­n±µ¨ülodoquinol ¥H¨¾´_µo
Cªk©w¶Ç¬V¯f¡A¥²¶·³ø§i¦a¤è»P¤¤¥¡½Ã¥Í¾÷Ãö
D¥H¤W¬Ò¬O
8.
(D)
½Ð°Ý¥H¤U¦C¨º¨Ç¯f­ì©Ò¤Þ°_ªº¯e¯f¡A¬Oªk©w¶Ç¬V¯f¡H
A¶Ë´H¨Fªù¤óµß
BÀN¶Ã©·µß
C§Ó¶P¤óµg¯e±ìµß
D¥H¤W¬Ò¬O
9.
(D)
¯f±w¥X²{¥H¤U¦óºØ¯f¼x®É¡A¥²¶·«Øij¶i¦æ·R´þ¯f¬rÀËÅç¡H
A±ö¬r
B¤fµÄ­¹¹D©À¯]µß·P¬V
C¥Í´Þ¾¹©´¯l
D¥H¤W¬Ò¬O
10.
(D)
¬ÛÃöµg¯eªü¦Ì¤Ú­ìÂηP¬Vªº±Ô­z¡A¦óªÌ¬°¬O¡H
Aµg¯eªü¦Ì¤Ú­ìÂηP¬V«¬¬OÀç¾iÅé
B¥D­n±H¥Í³¡¦ì¬O¤p¸z
C¥u¦³¸z¹D©M¨x³¡¦ìªº«]­­·P¬V¡A¨Ã¤£·|³y¦¨¨ä¥L³¡¦ìªºÁwºÅ
D¥¥°ü©MÀç¾i¤£¨}ªº±wªÌ¡A®e©öµo¥ÍÄY­««¬¬Æ¦Ü­P©Rªº¤j¸zª¢©ÎÁwºÅ


Top of Page